Drug profile · INN
idarucizumab
PRAXBIND
idarucizumab (PRAXBIND) is a dabigatran sequestering agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — idarucizumab
- US status
- approved
- Class
- Various (V03)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
idarucizumab (PRAXBIND) is a dabigatran sequestering agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dabigatran sequestering agent
Primary target: Dabigatran
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is idarucizumab?
idarucizumab (PRAXBIND) is a dabigatran sequestering agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for idarucizumab?
PRAXBIND is a marketed brand name for idarucizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of idarucizumab?
idarucizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.